Ways to help
About us
Contact Us
Home >
Feb 2017
Trish Foundation contributes to first-ever discovery
Jun 2017
Researchers funded by the Trish Foundation making great progress
Dec 2017
Announcement by NHMRC
Jan 2018
2018 Round of Funding Four new Projects announced
Jun 2018
Exciting regrowth of nerve fibres
Jun 2018
Dr Merson secures $1 million from NHMRC
Jun 2018
Findings submitted for publication
Jan 2019
New Research Projects commencing 2019 announced


The vitamin D MS Prevention Trial – PrevANZ
is a world-first clinical trial that will test whether vitamin D supplementation can prevent MS in those at risk of developing the disease.

This is a Phase IIb placebo-controlled, randomised trial – this is a phase in the clinical trials pipeline that looks at both safety and efficacy as well as identifying the most appropriate dose. The trial aims to identify whether, and at what dose, vitamin D supplements can prevent multiple sclerosis in people with a first episode of symptoms that may be a precursor to MS (known as clinically isolated syndrome or CIS). This might include symptoms such as blurred vision (optic neuritis) or limb weakness (transverse myelitis) (these symptoms may also be described as a first demyelinating event).

The need for the vitamin D MS prevention trial has arisen from a now significant body of evidence for the role that vitamin D deficiency plays in MS. However, to date there has not been a clinical trial conducted to provide the necessary evidence on the benefits that can be expected from vitamin D supplementation or the optimal dose.

MS Research Australia and colleagues in the MS research community see this trial as a high priority and an area in which the expertise in Australia and New Zealand can contribute significantly to the prevention and better treatment of MS globally.

A team of clinicians and researchers from Australia and New Zealand, with expertise in MS neurology, MS clinical trials, endocrinology and epidemiology has been assembled to oversee the trial.  The Trish Foundation is proud to have made a contribution to PrevANZ.

Recruitment for the trial is ongoing, and the team is excited to have reached 67% of our target enrolment of 240 people. It is expected the trial will be complete in 2019.

Trish Foundation & MS Research Australia Working together to find a cure for MS
Copyright © Trish Multiple Sclerosis Research Foundation. All rights reserved.